These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 22437211

  • 1. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H, Lavie CJ, Ventura HO.
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [Abstract] [Full Text] [Related]

  • 2. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G.
    J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
    [Abstract] [Full Text] [Related]

  • 3. The vasodilatory beta-blockers.
    Pedersen ME, Cockcroft JR.
    Curr Hypertens Rep; 2007 Aug; 9(4):269-77. PubMed ID: 17686376
    [Abstract] [Full Text] [Related]

  • 4. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.
    Black HR, Greenberg BH, Weber MA.
    Am J Med; 2010 Nov; 123(11):S2. PubMed ID: 21035578
    [Abstract] [Full Text] [Related]

  • 5. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J, Barbosa L, Silva JA, Bertoquini S.
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [Abstract] [Full Text] [Related]

  • 6. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 7. Beta-blockers for hypertension: are they going out of style?
    Che Q, Schreiber MJ, Rafey MA.
    Cleve Clin J Med; 2009 Sep; 76(9):533-42. PubMed ID: 19726558
    [Abstract] [Full Text] [Related]

  • 8. Beta-blockers in the treatment of hypertension: new data, new directions.
    Weber MA, Bakris GL, Giles TD, Messerli FH.
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):234-8. PubMed ID: 18326967
    [No Abstract] [Full Text] [Related]

  • 9. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL, Saseen JJ.
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [Abstract] [Full Text] [Related]

  • 10. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 11. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J, Faülhaber HD.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():77-82. PubMed ID: 15700490
    [Abstract] [Full Text] [Related]

  • 12. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr 27; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

  • 13. What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?
    Pedersen ME, Cockcroft JR.
    Curr Opin Cardiol; 2009 Jul 27; 24(4):325-32. PubMed ID: 19417638
    [Abstract] [Full Text] [Related]

  • 14. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 27; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 15. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug 27; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

  • 16. Influence of salt intake on the antihypertensive effect of carvedilol.
    Ruilope LM, Lahera V.
    J Hypertens Suppl; 1993 Jun 27; 11(4):S17-9. PubMed ID: 8104238
    [Abstract] [Full Text] [Related]

  • 17. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE, Philipp T.
    Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442
    [Abstract] [Full Text] [Related]

  • 18. Use of carvedilol in hypertension: an update.
    Leonetti G, Egan CG.
    Vasc Health Risk Manag; 2012 Nov 10; 8():307-22. PubMed ID: 22661898
    [Abstract] [Full Text] [Related]

  • 19. Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
    DiNicolantonio JJ, Hackam DG.
    Expert Rev Cardiovasc Ther; 2012 Jan 10; 10(1):13-25. PubMed ID: 22149523
    [Abstract] [Full Text] [Related]

  • 20. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E.
    Curr Diabetes Rev; 2010 Jul 10; 6(4):215-21. PubMed ID: 20459394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.